Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status.
Tomao F, Bardhi E, Di Pinto A, Sassu CM, Biagioli E, Petrella MC, Palaia I, Muzii L, Colombo N, Panici PB. Tomao F, et al. Among authors: biagioli e. Cancer Treat Rev. 2019 Nov;80:101909. doi: 10.1016/j.ctrv.2019.101909. Epub 2019 Oct 9. Cancer Treat Rev. 2019. PMID: 31629204 Review.
A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma.
Gadducci A, Grosso F, Scambia G, Raspagliesi F, Colombo N, Grignani G, Casali P, Sanfilippo R, Buonadonna A, Santoro A, Bruzzone M, Artioli G, Lorusso D, Biagioli E, Fossati R, Galli F, Negri E, Rulli E, Torri V, D'Incalci M. Gadducci A, et al. Among authors: biagioli e. Br J Cancer. 2018 Aug;119(5):565-571. doi: 10.1038/s41416-018-0190-y. Epub 2018 Jul 30. Br J Cancer. 2018. PMID: 30057406 Free PMC article. Clinical Trial.
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer.
Colombo N, Zaccarelli E, Baldoni A, Frezzini S, Scambia G, Palluzzi E, Tognon G, Lissoni AA, Rubino D, Ferrero A, Farina G, Negri E, Pesenti Gritti A, Galli F, Biagioli E, Rulli E, Poli D, Gerardi C, Torri V, Fossati R, D'Incalci M. Colombo N, et al. Among authors: biagioli e. Br J Cancer. 2019 Oct;121(9):744-750. doi: 10.1038/s41416-019-0584-5. Epub 2019 Sep 20. Br J Cancer. 2019. PMID: 31537908 Free PMC article. Clinical Trial.
Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer.
Colombo N, Tomao F, Benedetti Panici P, Nicoletto MO, Tognon G, Bologna A, Lissoni AA, DeCensi A, Lapresa M, Mancari R, Palaia I, Tasca G, Tettamanzi F, Alvisi MF, Rulli E, Poli D, Carlucci L, Torri V, Fossati R, Biagioli E; BAROCCO study group. Colombo N, et al. Among authors: biagioli e. Gynecol Oncol. 2022 Mar;164(3):505-513. doi: 10.1016/j.ygyno.2022.01.015. Epub 2022 Jan 19. Gynecol Oncol. 2022. PMID: 35063281 Clinical Trial.
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.
Colombo N, Gadducci A, Sehouli J, Rulli E, Mäenpää J, Sessa C, Montes A, Ottevanger NB, Berger R, Vergote I, D'Incalci M, Churruca Galaz C, Chekerov R, Nyvang GB, Riniker S, Herbertson R, Fossati R, Barretina-Ginesta MP, Deryal M, Mirza MR, Biagioli E, Iglesias M, Funari G, Romeo M, Tasca G, Pardo B, Tognon G, Rubio-Pérez MJ, DeCensi A, De Giorgi U, Zola P, Benedetti Panici P, Aglietta M, Arcangeli V, Zamagni C, Bologna A, Westermann A, Heinzelmann-Schwarz V, Tsibulak I, Wimberger P, Poveda A; INOVATYON study group. Colombo N, et al. Among authors: biagioli e. Br J Cancer. 2023 Apr;128(8):1503-1513. doi: 10.1038/s41416-022-02108-7. Epub 2023 Feb 9. Br J Cancer. 2023. PMID: 36759720 Free PMC article. Clinical Trial.
Radiosurgery for intracranial meningiomas: A systematic review and meta-analysis.
Pinzi V, Biagioli E, Roberto A, Galli F, Rizzi M, Chiappa F, Brenna G, Fariselli L, Floriani I. Pinzi V, et al. Among authors: biagioli e. Crit Rev Oncol Hematol. 2017 May;113:122-134. doi: 10.1016/j.critrevonc.2017.03.005. Epub 2017 Mar 12. Crit Rev Oncol Hematol. 2017. PMID: 28427502 Review.
Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma.
Silvani A, De Simone I, Fregoni V, Biagioli E, Marchioni E, Caroli M, Salmaggi A, Pace A, Torri V, Gaviani P, Quaquarini E, Simonetti G, Rulli E, D'Incalci M; Italian Association of Neuro-Oncology. Silvani A, et al. Among authors: biagioli e. J Neurooncol. 2019 May;142(3):455-462. doi: 10.1007/s11060-019-03116-z. Epub 2019 Feb 6. J Neurooncol. 2019. PMID: 30726533 Clinical Trial.
40 results